{"filing":{"accession_number":"0001493152-26-030408","cik":"0001430306","ticker":"TNXP","company_name":"Tonix Pharmaceuticals Holding Corp.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1430306/000149315226030408/form8-k.htm"},"events":[{"id":14451,"run_id":12864,"accession_number":"0001493152-26-030408","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Tonix announced the first patient enrollment in HORIZON, a Phase 2 clinical trial evaluating TNX-102 SL for major depressive disorder. This represents a material operational and clinical development milestone for the company's pipeline expansion into a new indication, with approximately 360 patients expected to enroll in what is described as a potentially pivotal trial.","company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":11890,"accession_number":"0001493152-26-030408","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Tonix announced the first patient enrollment in HORIZON, a Phase 2 clinical trial evaluating TNX-102 SL for major depressive disorder. This represents a material operational and clinical development milestone for the company's pipeline expansion into a new indication. While not a specific named event type (not earnings, M\u0026A, impairment, etc.), this clinical trial initiation is a significant operational event that would affect a reasonable investor's assessment of the company's progress and pipeline value, particularly given the large market opportunity (21+ million U.S. adults with MDD annually) and the company's commercial-stage status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T11:06:40.981194+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11891,"accession_number":"0001493152-26-030408","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces the first patient enrollment in the HORIZON Phase 2 clinical trial of TNX-102 SL for major depressive disorder (MDD). This is a material operational and clinical development milestone for a biotechnology company with an approved product (TONMYA for fibromyalgia) now expanding into a new indication. The trial is described as \"potentially pivotal\" with approximately 360 patients expected to enroll, representing a significant advancement in the company's pipeline and commercial strategy. While this is clearly an operational/clinical event rather than a financial, governance, or legal matter, it does not fit neatly into the predefined categories and thus warrants classification as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T11:06:40.981194+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11890,"accession_number":"0001493152-26-030408","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Tonix announced the first patient enrollment in HORIZON, a Phase 2 clinical trial evaluating TNX-102 SL for major depressive disorder. This represents a material operational and clinical development milestone for the company's pipeline expansion into a new indication. While not a specific named event type (not earnings, M\u0026A, impairment, etc.), this clinical trial initiation is a significant operational event that would affect a reasonable investor's assessment of the company's progress and pipeline value, particularly given the large market opportunity (21+ million U.S. adults with MDD annually) and the company's commercial-stage status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T11:06:40.981194+00:00","company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","filing_date":"2026-06-29"},{"id":11891,"accession_number":"0001493152-26-030408","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces the first patient enrollment in the HORIZON Phase 2 clinical trial of TNX-102 SL for major depressive disorder (MDD). This is a material operational and clinical development milestone for a biotechnology company with an approved product (TONMYA for fibromyalgia) now expanding into a new indication. The trial is described as \"potentially pivotal\" with approximately 360 patients expected to enroll, representing a significant advancement in the company's pipeline and commercial strategy. While this is clearly an operational/clinical event rather than a financial, governance, or legal matter, it does not fit neatly into the predefined categories and thus warrants classification as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T11:06:40.981194+00:00","company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","filing_date":"2026-06-29"}]}